Clinical Trials Browser

Phase 1 × Terminated × Vemurafenib × Clear all

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02818023 2022-01-03

Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma

Phase 1 Terminated

Melanoma

NCT01585415 2019-11-21

Vemurafenib and White Blood Cell Therapy for Advanced Melanoma

Phase 1 Terminated

Melanoma, Neoplasm Metastasis

NCT01876641 2018-09-19

ML28604

Phase 1 Terminated

Melanoma

NCT01611675 2017-04-06

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

Phase 1 Terminated

Melanoma, Neoplasm Metastasis

NCT01519323 2016-10-10

BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Phase 1 Terminated

6 enrolled 10 charts

Melanoma

NCT01400451 2015-01-01

Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

Phase 1 Terminated

18 enrolled 9 charts

Melanoma

NCT01835184 2014-09-25

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

Phase 1 Terminated

Melanoma